|
LOC110806263
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Urinary TERT promoter mutations as non-invasive biomarkers for the comprehensive detection of urothelial cancer.
|
31122840 |
2019 |
|
LOC110806263
|
Malignant Neoplasms
|
0.100 |
GeneticVariation |
BEFREE |
Absence of TERT promoter mutations in colorectal precursor lesions and cancer.
|
29473934 |
2019 |
|
LOC110806263
|
Malignant Neoplasms
|
0.100 |
GeneticVariation |
BEFREE |
The mechanism of the synergistic effect between BRAFV600E and TERT promoter mutations on cancer invasiveness and progression in PTC may be explained by increased TERT expression, which may result from the BRAF-induced upregulation of several ETS transcription factors.
|
30999281 |
2019 |
|
LOC110806263
|
Malignant Neoplasms
|
0.100 |
GeneticVariation |
BEFREE |
Two hotspot mutations in the TERT promoter region, c.-124C > T (C228T) and c.-146C > T (C250T), occur in various cancer types including thyroid cancer.
|
31408918 |
2019 |
|
LOC110806263
|
Malignant Neoplasms
|
0.100 |
GeneticVariation |
BEFREE |
TERT promoter mutations occur in the majority of glioblastoma, bladder cancer (BC), and other malignancies while the ETS family transcription factors GABPA and its partner GABPB1 activate the mutant TERT promoter and telomerase in these tumors.
|
31802036 |
2019 |
|
LOC110806263
|
Malignant Neoplasms
|
0.100 |
GeneticVariation |
BEFREE |
Although TERT promoter mutations (TPMs) are a major cancer-associated genetic mechanism of TERT upregulation, many cancers exhibit TERT upregulation without TPMs.
|
30358567 |
2019 |
|
LOC110806263
|
Malignant Neoplasms
|
0.100 |
GeneticVariation |
BEFREE |
After many types of research focusing on the mutations rate in malignant tumors, the main role of TERT promoter mutations has been changed to the preoperative diagnosis and prognosis of TC, according to their high prevalence in aggressive TC.
|
30024548 |
2018 |
|
LOC110806263
|
Malignant Neoplasms
|
0.100 |
GeneticVariation |
BEFREE |
While paediatric fibroepithelial lesions can have cellular stroma potentially raising concern for phyllodes tumour, their lack of TERT promoter and cancer driver mutations is reassuring.
|
29969836 |
2018 |
|
LOC110806263
|
Malignant Neoplasms
|
0.100 |
GeneticVariation |
BEFREE |
The unique oncogene duet of coexisting BRAF V600E and TERT promoter mutations are widely found to be a robust genetic background promoting human cancer aggressiveness, but the mechanism is unclear.
|
29422527 |
2018 |
|
LOC110806263
|
Malignant Neoplasms
|
0.100 |
GeneticVariation |
BEFREE |
Therapeutic options for targeting tumors with TERT promoter mutations are currently limited, although a variety of novel approaches are under development.Cancer 2018;124:1288-96.© 2017 American Cancer Society.
|
29211306 |
2018 |
|
LOC110806263
|
Malignant Neoplasms
|
0.100 |
GeneticVariation |
BEFREE |
Mutations in BAF complex and PI3K pathway genes co-occurred more frequently in TERTp-wt GBMs (p = 0.0002), an association that has been observed in other cancers, suggesting a functional interaction indicative of a distinct pathway of gliomagenesis.
|
30333046 |
2018 |
|
LOC110806263
|
Malignant Neoplasms
|
0.100 |
GeneticVariation |
BEFREE |
Somatic telomerase reverse transcriptase (TERT) promoter mutations have been recently identified in several types of malignant tumors, including thyroid neoplasia; however, the actual role of TERT mutations in thyroid tumorigenesis is still under debate.
|
29435002 |
2018 |
|
LOC110806263
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
TERT promoter) are considered cancer drivers for HCC development with variable frequencies in different geographic regions depending on the etiology and environmental factors.
|
28529542 |
2017 |
|
LOC110806263
|
Malignant Neoplasms
|
0.100 |
GeneticVariation |
BEFREE |
We confirmed the absence of TERT promoter mutations in benign follicular neoplasms and found a low frequency of TERT promoter mutations in our selected cohort of low-risk follicular-patterned malignancies, speculating their role in the progression and de-differentiation of thyroid cancer.
|
28975450 |
2017 |
|
LOC110806263
|
Malignant Neoplasms
|
0.100 |
GeneticVariation |
BEFREE |
TERT promoter mutation was rare but very specific for malignancy (5.5%) suggesting that it could be of interest in patients with indeterminate cytology.
|
29094776 |
2017 |
|
LOC110806263
|
Malignant Neoplasms
|
0.100 |
GeneticVariation |
BEFREE |
For rs2736100, the cancer risk genotype CC was significantly associated with a reduced incidence of TERT promoter mutations compared to AA + AC variants [Odds ratio (OR): 0.181, 95% Confidence interval (CI): 0.0543-0.601, P = 0.004].
|
28416747 |
2017 |
|
LOC110806263
|
Malignant Neoplasms
|
0.100 |
GeneticVariation |
BEFREE |
The most common molecular anomalies in this malignancy are mutations in the TERT promoter, TP53, CTNNB1, AXIN1, ARID1A, CDKN2A and CCND1 genes.
|
28854942 |
2017 |
|
LOC110806263
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
In summary, our study has identified a novel substrate for TIP60 catalytic activity and a unique repressive mechanism acting at the TERT promoter in virus-induced malignancies.
|
29045464 |
2017 |
|
LOC110806263
|
Malignant Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
Aberrant CpG dinucleotide methylation in a specific region of the telomerase reverse transcriptase (TERT) promoter is associated with increased TERT mRNA levels and malignancy in several cancer types.
|
28284778 |
2017 |
|
LOC110806263
|
Malignant Neoplasms
|
0.100 |
PosttranslationalModification |
BEFREE |
Induction of telomerase reverse transcriptase (TERT) expression coupled with telomerase activation is essential for cancer development/progression, while aberrant TERT promoter methylation has been linked to TERT induction in oncogenesis.
|
28754720 |
2017 |
|
LOC110806263
|
Malignant Neoplasms
|
0.100 |
GeneticVariation |
BEFREE |
We and others have associated the presence of TERT promoter mutations with metastisation/survival in several types of cancer.
|
28057768 |
2017 |
|
LOC110806263
|
Malignant Neoplasms
|
0.100 |
GeneticVariation |
BEFREE |
Human telomerase reverse transcriptase (TERT) promoter mutations are important genetic alterations in many kinds of human malignancies, including glioma.
|
27230769 |
2016 |
|
LOC110806263
|
Malignant Neoplasms
|
0.100 |
PosttranslationalModification |
BEFREE |
A cancer specific hypermethylation signature of the TERT promoter predicts biochemical relapse in prostate cancer: a retrospective cohort study.
|
27437772 |
2016 |
|
LOC110806263
|
Malignant Neoplasms
|
0.100 |
GeneticVariation |
BEFREE |
Among these, mutations in the telomerase reverse transcriptase (TERT) promoter have been correlated to malignant tumors, characterized by highest recurrence and decreased patients' survival.
|
25951319 |
2016 |
|
LOC110806263
|
Malignant Neoplasms
|
0.100 |
GeneticVariation |
BEFREE |
A TERT promoter mutation was independently associated with poorer overall survival in patients with differentiated thyroid cancer (10-year survival rate, 66.2% vs 98.3% for wild type; adjusted HR, 7.18; 95% CI: 2.77-18.59) and in patients with papillary cancer (74.2% vs 99.3%; 14.20; 3.03-66.68).
|
27528624 |
2016 |